Quantification of Bispecific Antibody Mediated T-cell Activation
Newsletter

Quantification of Bispecific Antibody Mediated T-cell Activation

The momentum behind bispecific antibody development continues to grow, driven by the need for more targeted and effective immunotherapies. As CD3‑engaging bispecifics become a central focus, developers need robust, sensitive, mode‑of‑action–reflective tools to confidently assess their performance. 

Our latest poster explores how Svar’s iLite® CD3‑responsive reporter cell line supports this evolving landscape with reliable and biologically relevant CD3‑activation measurements. 

Download the poster to explore the data and insights. 

Fill in the form to download the poster